argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
01 jun 2016 - 07:11
Statutaire naam
argenx SE
Titel
argenx announces private placement of 2,703,000 new shares for an aggregate amount of €30 million with institutional investors
Bericht
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
Breda, the Netherlands / Ghent, Belgium, 1 June 2016 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it entered into placement agreements with predominantly US institutional investors relating to the issue of a total of 2,703,000 new shares for an aggregate amount of €30,003,300. The issue price per new share in the financing is €11.10 and represents a discount of 2.6 % compared to the €11.40 closing price of the argenx share on Euronext Brussels on 31 May 2016.
Gerelateerde downloads
Datum laatste update: 28 juli 2024